Moderna (MRNA) and Merck (MRK) shares surged after a large trial demonstrated their investigational mRNA melanoma vaccine reduced recurrence, lifting the oncology pipeline outlook and driving gains across cancer immunotherapy stocks.
Moderna shares surged after a large trial showed its mRNA melanoma vaccine, developed with Merck, cut recurrence. The readout strengthens Moderna's oncology pipeline beyond Covid vaccines and supports a new revenue stream. Markets repriced MRNA higher on the data.
Moderna's mRNA melanoma vaccine, developed with Merck, cut recurrence in a large trial, boosting its oncology outlook.
It validates Moderna's mRNA platform beyond infectious disease vaccines and opens a new cancer immunotherapy market.
The trial readout lifted shares sharply as investors priced in a larger oncology franchise, though approval and commercialization still lie ahead.
Merck shares advanced after the melanoma vaccine developed with Moderna showed success in a large trial. The data bolster Merck's immuno-oncology franchise, where the company partners with Moderna on the mRNA vaccine.
Merck shares climbed because the melanoma vaccine it developed with Moderna succeeded in a large trial, strengthening its oncology business.
Merck is developing the mRNA cancer vaccine in partnership with Moderna, combining its immuno-oncology expertise.
The positive data support Merck's position in the growing cancer immunotherapy market and could add a new product line.
Moderna and Merck shares rallied after a large clinical trial showed their investigational mRNA melanoma vaccine reduced the risk of cancer recurrence. The data strengthen the case for personalized cancer immunotherapy and point to a new revenue stream for both drugmakers. The readout lifted both stocks sharply as investors repriced the oncology opportunity.
A large trial found the mRNA shot helped cut melanoma recurrence, sending both stocks higher.
The melanoma vaccine success validated their cancer pipeline and expanded the commercial opportunity.
The article describes an mRNA-based melanoma vaccine from Moderna and Merck.